<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DELATESTRYL- testosterone enanthateÂ injection, solutionÂ </strong><br>Endo Pharmaceuticals Solutions Inc.<br></p></div>
<h1>Delatestryl</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_23bac07f-830a-4e21-b003-925c67bb0fcc"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Multiple Dose Vial</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_df3e7758-2044-46cb-a45b-eeafb4c4422b"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) provides testosterone enanthate, a derivative of the primary endogenous androgen testosterone, for intramuscular administration. In their active form, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> have a 17-beta-hydroxy group. Esterification of the 17-beta-hydroxy group increases the duration of action of testosterone; hydrolysis to free testosterone occurs <span class="Italics">in vivo</span>. Each mL of sterile, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution provides 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol (chloral derivative) as a preservative.</p>
<p>Testosterone enanthate is designated chemically as androst-4-en-3-one, 17-[(1-oxoheptyl)-oxy]-, (17Î²)-. Structural formula:</p>
<div class="Figure"><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67e2cc36-a379-11dc-8314-0800200c9a66&amp;name=delatestryl-1.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_e916cc3a-11b0-4acc-b0fe-a6a823856d6d"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement; vocal chord thickening; alterations in body musculature; and fat distribution.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> also cause retention of nitrogen, sodium, potassium, and phosphorus, and decreased urinary excretion of calcium. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers. In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).</p>
<p>There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence, and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_c9914276-3c7a-4c4f-9f77-28dfa98813f6"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">PHARMACOKINETICS</span></h1>
<p class="First">Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus testosterone enanthate can be given at intervals of two to four weeks.</p>
<p>Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about two percent is free. Generally, the amount of this sex-hormone binding globulin (SHBG) in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about six percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways. There are considerable variations of the half-life of testosterone as reported in the literature, ranging from 10 to 100 minutes.</p>
<p>In responsive tissues, the activity of testosterone appears to depend on reduction to dihydrotestosterone (DHT), which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_daf7500d-8bd5-416a-87f7-904a108f4b1c"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First"><span class="Bold">Males<br></span>DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. </p>
<p><span class="Italics">Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span></span> (congenital or acquired) â€“ Testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome, or orchidectomy.</p>
<p><span class="Italics">Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span></span> (congenital or acquired) â€“ Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.)</p>
<p>If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.</p>
<p>Safety and efficacy of DELATESTRYL in men with â€œage-related hypogonadismâ€? (also referred to as â€œlate-onset hypogonadismâ€?) have not been established.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">Delayed puberty</span> </span>â€“ DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) may be used to stimulate puberty in carefully selected males with clearly <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. These patients usually have a familial pattern of <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>).</p>
<p><span class="Bold">Females<br></span><span class="Italics">Metastatic mammary cancer </span>â€“ DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_38507e8d-543b-444a-a587-c8a0e46c9d42"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus. This <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> is related to the amount of drug given and the age of the fetus and is most likely to occur in the female fetus when the drugs are given in the first trimester. If the patient becomes pregnant while taking <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, she should be apprised of the potential hazard to the fetus.</p>
<p>This preparation is also contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">In patients with breast cancer and in immobilized patients, androgen therapy may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by stimulating <span class="product-label-link" type="condition" conceptid="78308" conceptname="Osteolysis">osteolysis</span>. In patients with cancer, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may indicate progression of bony <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, the drug should be discontinued and appropriate measures instituted.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> has been associated with the development of <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span> including hepatocellular carcinoma (see <span class="Bold"><a href="#LINK_69e8f1e7-57d3-45df-bd46-6ad2dc3bdfc8">PRECAUTIONS, Carcinogenesis</a></span>). <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis hepatis</span> can be a life-threatening or fatal complication.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined. Drug-induced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is reversible when the medication is discontinued.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
<p>There have been postmarketing reports of venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, including <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients using testosterone products, such as DELATESTRYL<span class="Sup">Â®</span>.Â  Evaluate patients who report symptoms of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, warmth and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in the lower extremity for DVT and those who present with acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> for PE.Â  If a venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> is suspected, discontinue treatment with DELATESTRYL<span class="Sup">Â®</span> and initiate appropriate workup and management<span class="Italics">.</span></p>
<p>Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use DELATESTRYL.</p>
<p>Due to sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be a serious complication in patients with preexisting cardiac, renal, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. In addition to discontinuation of the drug, diuretic therapy may be required. If the administration of testosterone enanthate is restarted, a lower dose should be used.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> frequently develops and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_98315018-3d74-4e3e-baa4-1beb243c1e48"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_2e420b2a-883d-4348-b0d9-2d4b0c42f8f7"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Women should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, clitoromegaly, and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is necessary to prevent irreversible <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>. Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following androgen use at high doses and is not prevented by concomitant use of estrogens. A decision may be made by the patient and the physician that some <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> will be tolerated during treatment for breast carcinoma.</p>
<p>Because <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may alter serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, caution should be used when administering these drugs to patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Serial determinations of serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> should be made and therapy adjusted accordingly. A causal relationship between <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_43c7869e-eba3-4fb1-a95a-45359acf0520"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Male adolescent patients receiving <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> for <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> should have bone development checked every six months.</p>
<p>The physician should instruct patients to report any of the following side effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<p><span class="Italics">Adult or adolescent males </span>â€“ too frequent or persistent erections of the penis.<br><span class="Italics">Women </span>â€“ <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods, or more facial hair.<br><span class="Italics">All patients</span> â€“ any <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_afc52619-e635-4f8a-9a76-d5c815341a68"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Clinical studies of DELATESTRYL did not include sufficient numbers of subjects, aged 65 and older, to determine whether they respond differently from younger subjects. Testosterone replacement is not indicated in geriatric patients who have age-related <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> only (â€œandropauseâ€?), because there is insufficient safety and efficacy information to support such use. Current studies do not assess whether testosterone use increases risks of prostate cancer, prostate <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, and cardiovascular disease in the geriatric population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0be473ac-e842-4b97-8d40-cd9535c68f23"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">Intramuscular Administration</span></h2>
<p class="First">When properly given, injections of DELATESTRYL are well tolerated. Care should be taken to slowly inject the preparation deeply into the gluteal muscle, being sure to follow the usual precautions for intramuscular administration, such as the avoidance of intravascular injection. There have been rare postmarketing reports of transient reactions involving urge to <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> fits, and <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> immediately after the injection of DELATESTRYL, an oil-based depot preparation (see <span class="Bold"><a href="#LINK_2ed94c9d-d780-4605-acc3-6f2521d64bbe">DOSAGE AND ADMINISTRATION</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_1038754f-59eb-45c2-bd95-0606b088b162"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">Laboratory Tests</span></h2>
<p class="First">Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy (see <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>).</p>
<p>Periodic (every six months) X-ray examinations of bone age should be made during treatment of pre-pubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.</p>
<p>Hemoglobin and hematocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_b8369f11-9019-4e03-ac46-ba174ebe42c7"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">When administered concurrently, the following drugs may interact with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<p><span class="Italics">Anticoagulants, oral </span>â€“ C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirement. Patients receiving oral anticoagulant therapy require close monitoring especially when <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are started or stopped.</p>
<p><span class="Italics">Antidiabetic drugs and insulin</span> â€“ In diabetic patients, the metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and insulin requirements.</p>
<p><span class="Italics">ACTH and corticosteroids </span>â€“ Enhanced tendency toward <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease.</p>
<p><span class="Italics">Oxyphenbutazone</span> â€“ Elevated serum levels of oxyphenbutazone may result.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_2d02d7d2-70dd-41f4-a00f-d52b88bf9412"></a><a name="section-8.7"></a><p></p>
<h2><span class="Bold">Drug/Laboratory Test Interferences</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T<span class="Sub">4</span> serum levels and increased resin uptake of T<span class="Sub">3</span> and T<span class="Sub">4</span>. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_69e8f1e7-57d3-45df-bd46-6ad2dc3bdfc8"></a><a name="section-8.8"></a><p></p>
<h2><span class="Bold">Carcinogenesis</span></h2>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.</p>
<p>There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_42f61377-5d89-4799-ad47-bdd3c91ec0f7"></a><a name="section-8.9"></a><p></p>
<h2><span class="Bold">Pregnancy: Teratogenic Effects</span></h2>
<p class="First">Category X (see <span class="Bold"><a href="#LINK_38507e8d-543b-444a-a587-c8a0e46c9d42">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_d1036259-c9c3-4f81-8371-3e830c42ba12"></a><a name="section-8.10"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">It is not known whether <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_2eecdf60-f483-4b91-8663-c1130be471b9"></a><a name="section-8.11"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Androgen therapy should be used very cautiously in pediatric patients and only by specialists who are aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every six months by an X-ray of the hand and wrist (see <span class="Bold"><a href="#LINK_daf7500d-8bd5-416a-87f7-904a108f4b1c">INDICATIONS AND USAGE</a></span>, and <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_d8168b3a-5453-4895-90fd-7c6c0bd0fa67"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First"><span class="Italics">Endocrine and Urogenital, Female</span> â€“ The most common side effects of androgen therapy are <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and other menstrual irregularities, inhibition of gonadotropin secretion, and <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are discontinued. When administered to a pregnant woman, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus. </p>
<p><span class="Italics">Male</span> â€“ <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, and excessive frequency and duration of penile erections. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosages (see <span class="Bold"><a href="#LINK_e916cc3a-11b0-4acc-b0fe-a6a823856d6d">CLINICAL PHARMACOLOGY</a></span>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span> â€“ <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
<p><span class="Italics"> Skin and Appendages </span>â€“ <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4339092" conceptname="Male pattern alopecia">male pattern baldness</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span> </span>â€“ Retention of sodium, chloride, water, potassium, calcium (see <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>), and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
<p><span class="Italics">Gastrointestinal</span> â€“ <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests; rarely, hepatocellular neoplasms, <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> (see <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>).</p>
<p><span class="Italics">Hematologic </span>â€“ Suppression of clotting factors II, V, VII, and X; <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy; <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p><span class="Italics">Nervous System</span> â€“ Increased or decreased libido, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and generalized <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p><span class="Italics">Metabolic </span>â€“ Increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span> â€“ <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span></p>
<p><span class="Italics">Miscellaneous</span> â€“ Rarely, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>; <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_010b392c-dbe9-4af6-8d79-8beb6c517051"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<p class="First">DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_5ef9acf7-961d-4091-b812-b941f3897425"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">There have been no reports of acute overdosage with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_2ed94c9d-d780-4605-acc3-6f2521d64bbe"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Prior to initiating DELATESTRYL, confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> by ensuring that serum testosterone concentrations have been measured in the morning in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.</p>
<p> Dosage and duration of therapy with DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) will depend on age, sex, diagnosis, patientâ€™s response to treatment, and appearance of adverse effects. When properly given, injections of DELATESTRYL are well tolerated. Care should be taken to slowly inject the preparation deeply into the gluteal muscle, being sure to follow the usual precautions for intramuscular administration, such as the avoidance of intravascular injection (see <span class="Bold"><a href="#LINK_98315018-3d74-4e3e-baa4-1beb243c1e48">PRECAUTIONS</a></span>).</p>
<p>In general, total doses above 400 mg per month are not required because of the prolonged action of the preparation. Injections more frequently than every two weeks are rarely indicated. NOTE: Use of a wet needle or wet syringe may cause the solution to become cloudy; however this does not affect the potency of the material. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. DELATESTRYL is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution.</p>
<p><span class="Italics">Male <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>:</span> As replacement therapy, i.e., for eunuchism, the suggested dosage is 50 to 400 mg every 2 to 4 weeks.</p>
<p><span class="Italics">In males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>:</span> Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development (see <span class="Bold"><a href="#LINK_daf7500d-8bd5-416a-87f7-904a108f4b1c">INDICATIONS AND USAGE</a></span>, and <span class="Bold"><a href="#LINK_ac4b70d4-07ef-41a0-8419-4d9427f49f58">WARNINGS</a></span>).</p>
<p><span class="Italics">Palliation of inoperable mammary cancer in women:</span> A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_40a99a98-2447-4b53-8c80-b58b7cac7177"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) is available in 5 mL (200 mg/mL) multiple dose vials.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_91142008-214e-47b5-b866-6390c8e45d03"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">STORAGE</span></h1>
<p class="First">DELATESTRYL<span class="Sup">Â®</span> (Testosterone Enanthate Injection, USP) should be stored at room temperature. Warming and rotating the vial between the palms of the hands will redissolve any crystals that may have formed during storage at low temperatures.</p>
<p>For Prescription Use Only</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_815208ed-558e-4192-beb8-199bd74fd965"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>Endo Pharmaceuticals Solutions Inc.<br>Malvern, PA 19355</p>
<p>Medical Inquiries:<br>1-800-462-3636</p>
<p>Revised: 05/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_9d933fc7-0946-41fc-b388-56de7b7171a6"></a><a name="section-16"></a><p></p>
<h1>Package Label - Principal Display Panel â€“ Vial Carton<br>
</h1>
<div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67e2cc36-a379-11dc-8314-0800200c9a66&amp;name=delatestryl-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_072036ea-7ea9-417a-be4d-391cb1bc9ab6"></a><a name="section-17"></a><p></p>
<h1>Package Label - Principal Display Panel â€“ Vial Label<br>
</h1>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67e2cc36-a379-11dc-8314-0800200c9a66&amp;name=delatestryl-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DELATESTRYLÂ 		
					</strong><br><span class="contentTableReg">testosterone enanthate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67979-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TESTOSTERONE ENANTHATE</strong> (TESTOSTERONE) </td>
<td class="formItem">TESTOSTERONE ENANTHATE</td>
<td class="formItem">200Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SESAME OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67979-501-40</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA009165</td>
<td class="formItem">12/24/1953</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Endo Pharmaceuticals Solutions Inc.
							(178074951)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sandoz Canada Inc</td>
<td class="formItem"></td>
<td class="formItem">244062071</td>
<td class="formItem">MANUFACTURE(67979-501)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>66b1d912-3b15-416f-9144-4e04d994b860</div>
<div>Set id: 67e2cc36-a379-11dc-8314-0800200c9a66</div>
<div>Version: 5</div>
<div>Effective Time: 20150520</div>
</div>
</div>Â <div class="DistributorName">Endo Pharmaceuticals Solutions Inc.</div></p>
</body></html>
